Basu et al. [24] indicated that mTORis could prevent the rapid progression of post-transplantation renal cancer through the downregulation of the angiogenic cytokine vascular endothelial growth factor and the chemokine receptor CXCR3 and its ligands. This evidence concerns the gene VEGFA and renal carcinoma.